Clinical development of siltuximab.

about

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.

P2860

Q38763837-949FB425-1781-441F-9F5D-C689D99957DE

P2860

Clinical development of siltuximab.

Item

http://www.wikidata.org/entity/Q38489678

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Clinical development of siltuximab.

@en

type

Item

label

Clinical development of siltuximab.

@en

prefLabel

Clinical development of siltuximab.

@en

P1476

Clinical development of siltuximab.

@en

P2093

Christine C Davis

http://www.w3.org/2001/XMLSchema#string

Katherine S Shah

http://www.w3.org/2001/XMLSchema#string

Mary Jo Lechowicz

http://www.w3.org/2001/XMLSchema#string

P2860

A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.

Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

Localized mediastinal lymphnode hyperplasia resembling thymoma.

Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.

P2888

s11912-015-0453-1

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-015-0453-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1018680963

http://www.w3.org/2001/XMLSchema#string

P698

25986720

http://www.w3.org/2001/XMLSchema#string

Clinical development of siltuximab.

about

P2860

P2860

Clinical development of siltuximab.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698